B46.0

Clinical Causes: Inhalation of spores from Mucorales fungi found in the environment Compromised immune system due to conditions such as leukemia, lymphoma, or diabetes mellitus Use of immunosuppressive therapies, including steroids or chemotherapy Uncontrolled or severe diabetic ketoacidosis Recent organ or stem cell transplants Prolonged hospitalization and invasive medical procedures

Key Symptoms: Persistent cough, which may produce blood-tinged sputum Shortness of breath or difficulty breathing Chest pain or discomfort Fever, often high-grade Fatigue and malaise Unintentional weight loss Frequent or recurrent respiratory infections Wheezing or crackles heard on lung examination

Diagnosis Path: Diagnosing pulmonary mucormycosis involves a combination of clinical evaluation, imaging, and laboratory tests. Doctors typically start with a thorough medical history and physical exam, paying special attention to immune status and risk factors. Imaging studies like chest X-rays and CT scans can reveal characteristic lung abnormalities such as nodules, cavitary lesions, or areas of tissue death. Confirmatory diagnosis often requires sampling lung tissue through procedures like bronchoscopy or biopsy, followed by microscopic examination and microbiological cultures to identify Mucorales fungi.

Treatment Protocols: Treatment of pulmonary mucormycosis usually involves antifungal medications combined with surgical intervention in some cases. The mainstay therapy is high-dose antifungals such as amphotericin B, which requires close monitoring due to potential side effects. Isavuconazole or posaconazole may be used as alternative or adjunct therapies. Managing underlying health conditions, especially controlling blood sugar levels in diabetics, is essential. In many instances, surgical removal of infected lung tissue is necessary to prevent further spread. Early diagnosis and aggressive treatment are critical to improving survival chances.